Strategic Global Advisors LLC Takes $1.55 Million Position in Insulet Corporation $PODD

Strategic Global Advisors LLC bought a new stake in Insulet Corporation (NASDAQ:PODD) in the 4th quarter, Holdings Channel.com reports. The fund bought 5,443 shares of the medical instruments supplier’s stock, valued at approximately $1,547,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in PODD. Norges Bank acquired a new stake in shares of Insulet in the 4th quarter valued at $300,794,000. Worldquant Millennium Advisors LLC acquired a new stake in shares of Insulet in the 2nd quarter valued at $80,082,000. Jupiter Asset Management Ltd. acquired a new stake in shares of Insulet in the 4th quarter valued at $66,644,000. Squarepoint Ops LLC increased its stake in shares of Insulet by 11,905.8% in the 3rd quarter. Squarepoint Ops LLC now owns 227,270 shares of the medical instruments supplier’s stock valued at $70,165,000 after buying an additional 225,377 shares during the period. Finally, Westfield Capital Management Co. LP increased its stake in shares of Insulet by 91.9% in the 4th quarter. Westfield Capital Management Co. LP now owns 386,468 shares of the medical instruments supplier’s stock valued at $109,850,000 after buying an additional 185,081 shares during the period.

Insider Activity

In related news, Director Timothy C. Stonesifer purchased 2,790 shares of Insulet stock in a transaction dated Wednesday, June 3rd. The shares were acquired at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the transaction, the director directly owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.36% of the stock is owned by corporate insiders.

Insulet Price Performance

NASDAQ:PODD opened at $149.70 on Monday. Insulet Corporation has a 12-month low of $140.63 and a 12-month high of $354.88. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $10.37 billion, a P/E ratio of 34.81, a P/E/G ratio of 1.18 and a beta of 1.13. The stock’s fifty day simple moving average is $169.92 and its 200-day simple moving average is $231.93.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The business had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. During the same period last year, the company earned $1.02 EPS. The firm’s revenue was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities research analysts expect that Insulet Corporation will post 6.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth

PODD has been the subject of several research reports. Canaccord Genuity Group lowered their target price on Insulet from $435.00 to $249.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Barclays lowered their target price on Insulet from $286.00 to $198.00 and set an “underweight” rating for the company in a research note on Thursday, May 7th. Stifel Nicolaus lowered their target price on Insulet from $350.00 to $250.00 in a research note on Thursday, May 7th. Royal Bank Of Canada reissued an “outperform” rating and issued a $280.00 target price on shares of Insulet in a research note on Wednesday, May 27th. Finally, Citigroup lowered their target price on Insulet from $175.00 to $165.00 and set a “neutral” rating for the company in a research note on Thursday, May 28th. Twenty-one investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Insulet presently has an average rating of “Moderate Buy” and a consensus target price of $240.78.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.